Amid a backdrop of fluctuating global markets and evolving trade policies, Asian economies continue to demonstrate resilience, with China’s export growth and Japan’s strong corporate earnings providing positive signals. In such an environment, companies with high insider ownership often attract attention due to their potential for aligned interests between management and shareholders, making them appealing candidates for investors seeking growth opportunities.
|
Name |
Insider Ownership |
Earnings Growth |
|
Zhejiang Leapmotor Technology (SEHK:9863) |
15.6% |
60.7% |
|
Vuno (KOSDAQ:A338220) |
15.6% |
109.8% |
|
Techwing (KOSDAQ:A089030) |
19.1% |
68% |
|
Suzhou Sunmun Technology (SZSE:300522) |
35.4% |
77.7% |
|
Shanghai Huace Navigation Technology (SZSE:300627) |
24.3% |
24.3% |
|
Novoray (SHSE:688300) |
23.6% |
28.2% |
|
M31 Technology (TPEX:6643) |
30.8% |
95.5% |
|
Laopu Gold (SEHK:6181) |
35.5% |
43% |
|
Gold Circuit Electronics (TWSE:2368) |
31.4% |
32.8% |
|
Fulin Precision (SZSE:300432) |
12.8% |
43.7% |
Underneath we present a selection of stocks filtered out by our screen.
Simply Wall St Growth Rating: ★★★★★☆
Overview: ABL Bio Inc. is a biotech research company specializing in developing therapeutic drugs for immuno-oncology and neurodegenerative diseases, with a market cap of ₩4.45 trillion.
Operations: The company’s revenue is primarily generated from its biotechnology startups segment, amounting to ₩27.63 billion.
Insider Ownership: 26.6%
Earnings Growth Forecast: 49.5% p.a.
ABL Bio is poised for significant growth, with revenue expected to increase by 24.5% annually, outpacing the KR market’s 7.3% growth rate. The company is forecast to become profitable within three years, although its future Return on Equity remains low at 0.1%. Recent engagements include presentations at the ESMO Gastrointestinal Cancers Congress and upcoming earnings calls aimed at elucidating R&D and management strategies, highlighting active leadership involvement in strategic communication.
Simply Wall St Growth Rating: ★★★★☆☆
Overview: BYD Company Limited, along with its subsidiaries, operates in the automobiles and batteries sectors across the People’s Republic of China, Hong Kong, Macau, Taiwan, and internationally with a market cap of HK$1.06 trillion.
Operations: The company’s revenue segments include its operations in the automobiles and batteries sectors, generating income across China, Hong Kong, Macau, Taiwan, and international markets.
Insider Ownership: 28.6%
Earnings Growth Forecast: 15.9% p.a.
BYD is experiencing robust growth, with earnings projected to increase by 15.9% annually, surpassing the Hong Kong market’s average. The company’s revenue is also expected to grow at 13.5% per year. Recent strategic moves include a dealership agreement in Finland and a partnership with FC Internazionale Milano, enhancing its global presence and aligning with its expansion strategy in Europe. Despite changes in capital structure, insider ownership remains significant, supporting long-term growth objectives.
Simply Wall St Growth Rating: ★★★★☆☆
Overview: China XLX Fertiliser Ltd. is an investment holding company involved in the development, manufacture, and sale of urea both in Mainland China and internationally, with a market cap of HK$10.51 billion.
Operations: The company’s revenue is primarily derived from the sale of urea (CN¥8.45 billion), methanol (CN¥5.98 billion), compound fertiliser (CN¥7.02 billion), DMF (CN¥1.19 billion), and melamine (CN¥0.93 billion).
Insider Ownership: 17.9%
Earnings Growth Forecast: 27.1% p.a.
China XLX Fertiliser is poised for significant earnings growth, forecasted at 27.1% annually, outpacing the Hong Kong market. Despite a recent dip in net income to CNY 599.3 million for the first half of 2025, insider buying has been substantial over the past three months, indicating confidence in its growth trajectory. While trading at a favorable price-to-earnings ratio of 7x compared to peers, high debt levels remain a concern for investors.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.The analysis only considers stock directly held by insiders. It does not include indirectly owned stock through other vehicles such as corporate and/or trust entities. All forecast revenue and earnings growth rates quoted are in terms of annualised (per annum) growth rates over 1-3 years.
Companies discussed in this article include KOSDAQ:A298380 SEHK:1211 and SEHK:1866.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com